Alfred Altomari - Agile Thrpe CEO and President and Director
| AGRXDelisted Stock | USD 0.34 0.01 3.03% |
CEO
Mr. Alfred Altomari serves as Chairman of the Board, President, Chief Executive Officer of Agile Therapeutics, Inc. From 2008 to September 2010, Mr. Altomari was also a consultant to Agile. From 2003 to 2008, Mr. Altomari held multiple senior management positions at Barrier Therapeutics, Inc., including Chief Commercial Officer, Chief Operating Officer, and Chief Executive Officer. In 2008, in his role as Chief Executive Officer and as a member of Barrier board of directors, Mr. Altomari completed the successful sale of Barrier to Stiefel Laboratories, which was subsequently acquired by GlaxoSmithKline plc. From 1982 to 2003, Mr. Altomari held numerous executive roles in general management, commercial operations, business development, product launch preparation, and finance with Johnson Johnson. Mr. Altomari also serves on the board of directors of Insmed Inc. and Recro Pharma, Inc. since 2016.
| Age | 65 |
| Tenure | 8 years |
| Phone | 609 683 1880 |
| Web | https://www.agiletherapeutics.com |
Agile Thrpe Management Efficiency
The company has return on total asset (ROA) of (0.9671) % which means that it has lost $0.9671 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (13.6404) %, meaning that it created substantial loss on money invested by shareholders. Agile Thrpe's management efficiency ratios could be used to measure how well Agile Thrpe manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 2.21 M in liabilities with Debt to Equity (D/E) ratio of 3.95, implying the company greatly relies on financing operations through barrowing. Agile Thrpe has a current ratio of 0.63, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Agile Thrpe until it has trouble settling it off, either with new capital or with free cash flow. So, Agile Thrpe's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Agile Thrpe sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Agile to invest in growth at high rates of return. When we think about Agile Thrpe's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 10 records | CEO Age | ||
| David RPh | Evoke Pharma | 60 | |
| Chintu RPh | Amneal Pharmaceuticals Class | 52 | |
| Ilan MBA | PainreformLtd | 55 | |
| Keith Kendall | Aquestive Therapeutics | 66 | |
| Stephen Gunstream | Alpha Teknova | 44 | |
| Chintu Patel | Amneal Pharmaceuticals Class | 49 | |
| Chirag Patel | Amneal Pharmaceuticals Class | 57 | |
| James Hall | Lifecore Biomedical | 61 | |
| Janet Hall | Guardion Health Sciences | 65 | |
| David Gonyer | Evoke Pharma | 60 | |
Management Performance
| Return On Equity | -13.64 | ||||
| Return On Asset | -0.97 |
Agile Thrpe Leadership Team
Elected by the shareholders, the Agile Thrpe's board of directors comprises two types of representatives: Agile Thrpe inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Agile. The board's role is to monitor Agile Thrpe's management team and ensure that shareholders' interests are well served. Agile Thrpe's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Agile Thrpe's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Senior Officer | ||
| Jason Butch, VP Officer | ||
| Joseph DUrso, Controller | ||
| Robert ME, Senior Officer | ||
| Kathryn PharmD, Advisor | ||
| Alfred Altomari, CEO and President and Director | ||
| Matthew Riley, Head Communications | ||
| Amy Welsh, Senior Officer | ||
| Geoffrey Gilmore, Senior Officer | ||
| Scott Coiante, CFO and VP | ||
| MPH MD, Consultant |
Agile Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Agile Thrpe a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -13.64 | ||||
| Return On Asset | -0.97 | ||||
| Profit Margin | (0.70) % | ||||
| Operating Margin | (0.60) % | ||||
| Current Valuation | 633.86 K | ||||
| Shares Outstanding | 2.96 M | ||||
| Shares Owned By Insiders | 1.13 % | ||||
| Shares Owned By Institutions | 10.13 % | ||||
| Number Of Shares Shorted | 222.1 K | ||||
| Price To Earning | (4.74) X |
Pair Trading with Agile Thrpe
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agile Thrpe position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agile Thrpe will appreciate offsetting losses from the drop in the long position's value.Moving together with Agile Stock
| 0.82 | DVAX | Dynavax Technologies | PairCorr |
| 0.8 | EGRX | Eagle Pharmaceuticals | PairCorr |
Moving against Agile Stock
| 0.87 | HCM | HUTCHMED DRC | PairCorr |
| 0.87 | FTLF | FitLife Brands Common | PairCorr |
| 0.84 | ACB | Aurora Cannabis Financial Report 12th of June 2024 | PairCorr |
| 0.83 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
| 0.81 | ELTP | Elite Pharma | PairCorr |
The ability to find closely correlated positions to Agile Thrpe could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agile Thrpe when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agile Thrpe - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agile Thrpe to buy it.
The correlation of Agile Thrpe is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agile Thrpe moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agile Thrpe moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agile Thrpe can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Agile Stock
If you are still planning to invest in Agile Thrpe check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Agile Thrpe's history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |